Plasma Concentrations of Carotenoids, Retinol, and Tocopherols in Preeclamptic and Normotensive Pregnant Women

Cuilin Zhang1, Michelle A. Williams1,,–3, Sixto E. Sanchez4, Irena B. King2, Suzie Ware-Jauregui1, Gloria Larrabure5, Victor Bazul5 and Wendy M. Leisenring6

1 Department of Epidemiology, University of Washington, Seattle, WA.
2 Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA.
3 Center for Perinatal Studies, Swedish Medical Center, Seattle, WA.
4 Dos de Mayo Hospital, Lima, Peru.
5 Materno-Perinatal Institute, Lima, Peru.
6 Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA.


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
This case-control study was conducted in Lima, Peru, from June 1997 through January 1998 to assess whether plasma concentrations of carotenoids ({alpha}-carotene, ß-carotene, lycopene, lutein, zeaxanthin, ß-cryptoxanthin), retinol, and tocopherols ({alpha}-tocopherol and {gamma}-tocopherol) are decreased in women with preeclampsia. A total of 125 pregnant women with preeclampsia and 179 normotensive pregnant women were included. Plasma concentrations of antioxidants were determined using high performance liquid chromatography. After adjusting for maternal demographic, behavioral, and reproductive characteristics and total plasma lipid concentrations, the authors found a linear increase in risk of preeclampsia with increasing concentrations of {alpha}-tocopherol (odds ratio of the highest quartile = 3.13; 95% confidence interval: 1.06, 9.23, with the lowest quartile as the reference group; p value of the test of linear trend = 0.040). The risk of preeclampsia decreased across increasing quartiles of concentrations for retinol (odds ratio of the highest quartile = 0.32; 95% confidence interval: 0.15, 0.69, with the lowest quartile as the reference group; p value of the test of linear trend = 0.001). Some of these results are inconsistent with the prevailing hypothesis that preeclampsia is an antioxidant-deficient state. Preliminary findings confirm an earlier observation of increased plasma concentrations of {alpha}-tocopherol among women with preeclampsia as compared with normotensive pregnant women.

carotenoids; pre-eclampsia; pregnancy; risk factors; vitamin A; vitamin E

Abbreviations: CI, confidence interval; HPLC, high performance liquid chromatography; OR, odds ratio; SE, standard error


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Although the birth experience has never been as safe for mothers and infants as it is today, pregnancy-induced hypertension with proteinuria (i.e., preeclampsia) still occurs in 5–10 percent of all pregnancies and is still one of the leading causes of maternal and fetal mortality in developed and developing countries. Despite extensive research, the etiology of preeclampsia is still one of the major unsolved mysteries in obstetrics. It is widely accepted that endothelial cell dysfunction resulting in vascular permeability plays an important role in the pathophysiology of preeclampsia (1GoGoGoGoGoGo–7Go). The precise cause of vascular endothelial dysfunction, however, remains unknown. It has been suggested that free radicals are likely promoters of maternal vascular malfunction. Reactive oxygen species, particularly superoxide anions, evoke endothelial cell activation (8Go). Markers of lipid peroxidation have been noted to be increased in the plasma of women with preeclampsia (9Go). Antioxidants, such as carotenoids and tocopherols, due to their capacity of scavenging free radicals and their function as inhibitors of reactive oxygen species, are of increasing interest among investigators studying preeclampsia. Results from several recent studies suggest that there are imbalances between lipid peroxidation and antioxidant defenses in preeclampsia (10Go, 11Go). There is some evidence of a deficiency in protective antioxidant systems or increased utilization of antioxidants in preeclamptic compared with normotensive pregnancies (12Go, 13Go). Women with preeclampsia as compared with normotensive women have been shown to have lower plasma {alpha}-carotene, ß-carotene, and retinol levels (9Go). Although there are reports of decreased plasma concentrations of {alpha}-tocopherol in preeclampia, studies conducted in Finland (13Go), the United Kingdom (14Go), and the United States (15Go) suggest higher plasma {alpha}-tocopherol concentrations in preeclamptic women as compared with normotensive pregnant women. Reports concerning other lipid-soluble antioxidants in pregnancies complicated with preeclampsia are scarce.

To our knowledge, no results regarding the magnitude of the odds ratio of preeclampsia associated with varying concentrations of carotenoids, tocopherols, and retinol have been reported. Additionally, potential confounding factors of preeclampsia were not evaluated in most previous studies. We studied a large group of Peruvian women to examine the relation of plasma concentrations of carotenoids, tocopherols, and retinol, measured in the third trimester of pregnancy, with the risk of preeclampsia.


    MATERIALS AND METHODS
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
This case-control study was conducted at the Maternal and Perinatal Hospital of Lima and the Dos de Mayo Hospital in Lima, Peru, from June 1997 through January 1998. Details regarding data collection methods have been previously described (16GoGo–18Go). Briefly, cases eligible for inclusion were those women with a diagnosis of preeclampsia. Preeclampsia was defined as 1) a persistent (i.e., lasting more than 6 hours) 15-mmHg diastolic rise or a 30-mmHg rise in systolic blood pressure or 2) a persistent blood pressure of at least 140/90 mmHg and a urine protein concentration of >=30 mg/dl (or 1+ on a urine dipstick) in at least two random specimens collected at least 4 hours apart. Approximately 97 percent of the eligible cases who were approached and asked to participate in the study elected to do so (193 of 199 subjects). Controls were women with pregnancies uncomplicated by pregnancy-induced hypertension and proteinuria. Controls were frequency matched to cases for gestational age of admission (within 2 weeks) and on maternal age (within 5 years). Of the 204 controls approached, 196 (96 percent) agreed to participate in the study.

A standardized, structured questionnaire was used to collect information regarding maternal sociodemographic, medical, reproductive, and lifestyle characteristics during in-person interviews. All interviews were conducted in the hospital. Maternal and infant records were reviewed to collect detailed information concerning antepartum, labor, and delivery characteristics and the condition of the newborn infants. Maternal anthropometric measures (height, weight, and midarm circumference) were taken during the participants' hospital stay. Gestational age was based on the date of the last menstrual period and was confirmed by ultrasound examination. Prepregnancy body mass index, used as a measure of overall maternal adiposity, was calculated as weight (kg)/height (m)2. Blood samples collected in 10-ml ethylenediaminetetraacetic acid (EDTA) Vacutainer tubes (Becton Dickinson and Company, E. Rutherford, New Jersey) were immediately transported in a cooler with ice to the Blood Bank Laboratory of Dos de Mayo Hospital. Upon arrival at the laboratory, blood was centrifuged and plasma was divided into 1.0- to 2.0-ml aliquots, placed in cryovials, and stored at -70°C. Specimens were shipped on dry ice with blue ice packs to the United States for biochemical analyses.

Blood samples were available for 180 cases and 196 control subjects. After the exclusion of six cases and three control subjects with chronic hypertension diagnosed prior to pregnancy or during the first 20 weeks of the index pregnancy, 174 preeclampsia cases and 193 normotensive control subjects remained for study. Because maternal plasma antioxidant nutrients and lipid concentrations may change rapidly after parturition (19Go), we further excluded 49 preeclampsia cases and 14 controls for whom blood samples were drawn after delivery, thus leaving 125 cases and 179 controls for this research. Maternal sociodemographic and clinical characteristics were not materially different for those excluded subjects compared with those retained for this analysis.

Plasma antioxidant nutrients were measured by high performance liquid chromatography (HPLC). The HPLC assay was modified to expand analysis to include determination of lutein, zeaxanthin, and ß-cryptoxanthin concentrations. The extraction of analytes from plasma, the quality control parameters, and the HPLC methods were previously published (20Go). Briefly, a hexane extract of plasma was injected onto a 3-mm C-18 Spherisorb ODS-2 HPLC column (Alltech, Deerfield, Illinois) and eluted with an isocratic solvent consisting of 73 percent acetonitrile, 12 percent tetrahydrofuran, 8 percent methanol, 7 percent water, 0.025 percent ammonium acetate, and 0.05 percent diethylamine (volume/volume) at a flow rate of 1.2 ml/minute. Lutein, zeaxanthin, ß-cryptoxanthin, and lycopene were detected at 476 nm, {alpha}-carotene and ß-carotene were detected at 452 nm, {alpha}-tocopherol and {gamma}-tocopherol were detected at 292 nm, and retinol was detected at 325 nm. The coefficient of variation for pooled quality control samples was <=10 percent for all analytes. Plasma cholesterol was measured to calculate the ratio of vitamin E to cholesterol. Plasma total cholesterol concentrations were measured enzymatically (18Go). Total cholesterol measurements were standardized by the Lipid Standardization Program of the Centers for Disease Control and Prevention, Atlanta, Georgia. Triglycerides were analyzed by a glycerol phosphate oxidation assay. All laboratory analyses were performed without knowledge of pregnancy outcome.

The plasma tocopherol concentration is influenced by plasma lipoproteins that are transport molecules of the antioxidant (21Go). We controlled for potential confounding by plasma lipids in three ways. First, we calculated the ratio of plasma {alpha}-tocopherol to plasma total cholesterol concentrations. The ratio of {alpha}-tocopherol to cholesterol is considered by some investigators to be a biologically more relevant marker of vitamin E status than is {alpha}-tocopherol alone (22GoGoGo–25Go). Second, as described by Thurnham et al. (22Go), we calculated plasma total lipids as (2 x cholesterol + triglycerides) and calculated the ratio of {alpha}-tocopherol to total lipids. Third, we adjusted for plasma concentrations of cholesterol and/or plasma total lipids when analyzing the relation of plasma antioxidants with the risk of preeclampsia.

We examined the frequency distributions of maternal sociodemographic characteristics and medical and reproductive histories according to case-control status. Comparisons of categorical variables were made between case and control subjects using chi-squared or Fisher's exact tests. In order to compare our results with those from previous clinical studies concerning the relation between plasma antioxidants and preeclampsia, we calculated the mean and median values of plasma antioxidant concentrations for the two study groups. Student's t tests were used to evaluate mean differences in maternal plasma concentrations of antioxidant nutrients between cases and controls. Furthermore, because of the extremely skewed distributions of plasma concentrations of ß-cryptoxanthin, the Mann-Whitney U test was used to assess median differences for that analyte.

To further evaluate the association between preeclampsia and plasma antioxidants, we categorized each subject according to quartiles determined by the distribution of antioxidant concentrations in controls. Using the lowest category as the referent group, we calculated odds ratios (i.e., estimates of relative risk) and their 95 percent confidence intervals. The Mantel extension test for linear trend in proportions (26Go) was used in univariate analyses to test for a linear component of trend in the risk of preeclampsia in relation to each antioxidant. Logistic regression procedures were used to calculate maximum likelihood estimates for the coefficients and their standard errors. These estimates and their standard errors were then used to calculate odds ratios and 95 percent confidence intervals, adjusted for confounders (27Go). In logistic regression models, the significance for monotonic trend was assessed by treating the four quartiles as a continuous variable after assigning a score to each quartile (27Go). To assess confounding, we entered variables into a logistic regression model one at a time and then compared the adjusted and unadjusted odds ratios (27Go). Final logistic regression models included covariates that altered unadjusted odds ratios by at least 10 percent, as well as those covariates with a priori interest (e.g., maternal age and parity). The candidate confounding variables considered were maternal age, race/ethnicity, educational attainment, smoking during pregnancy, use of prenatal vitamins, plasma cholesterol concentrations, marital status, parity, prepregnancy body mass index, gestational age at blood collection, and whether the pregnancy was planned. All reported p values are two tailed, and confidence intervals were calculated at the 95 percent level.


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Sociodemographic and clinical characteristics of the study participants are presented in table 1. The maternal age distributions were similar for cases and controls. The mean plasma concentrations of total cholesterol were approximately 6 percent higher for cases as compared with controls. More cases (42.4 percent) reported not using prenatal vitamins during pregnancy than controls (38.5 percent). These differences, however, were not statistically significant. Cases were more likely to be nulliparous, to deliver lower birth weight infants, and to have a higher prepregnancy body mass index than controls. These differences were statistically significant.


View this table:
[in this window]
[in a new window]
 
TABLE 1. Distribution of preeclampsia cases and normotensive control subjects according to selective characteristics, Lima, Peru, 1997–1998

 
The mean plasma retinol concentrations among preeclampsia cases were 11 percent lower (0.77 vs. 0.87 µmol/liter) than those observed for controls (p < 0.001) (table 2). The mean value of plasma concentrations of {alpha}-tocopherol, the ratio of {alpha}-tocopherol to plasma cholesterol concentrations, and the ratio of {alpha}-tocopherol to total plasma lipids were higher (25.45 vs. 22.86 µmol/liter, 3.96 vs. 3.74, 1.562 vs. 1.517; p = 0.002, p = 0.033, p = 0.079, respectively) among cases than controls. No statistically significant differences in the mean plasma concentrations of {alpha}-carotene, ß-carotene, lutein, lycopene, zeaxanthin, and {gamma}-tocopherol between preeclampsia cases and controls were observed. Moreover, no statistically significant difference in the median plasma concentrations of ß-cryptoxanthin was noted for preeclampsia cases as compared with normotensive controls.


View this table:
[in this window]
[in a new window]
 
TABLE 2. Plasma concentrations (µmol/liter) of antioxidant nutrients among preeclamptic and normotensive pregnant women, Lima, Peru, 1997–1998

 
The unadjusted odds ratio for preeclampsia generally decreased across increasing quartiles of retinol concentration (odds ratio (OR) = 1.00, 0.44, 0.36, 0.40, respectively) (table 3). After adjusting for confounding by maternal age, the prepregnancy body mass index, prenatal vitamin use during pregnancy, parity, whether the pregnancy was planned, and maternal educational attainment, we found that women in the highest quartile experienced a 68 percent reduced risk of preeclampsia as compared with women in the lowest quartile (adjusted odds ratio = 0.32; 95 percent confidence interval (CI): 0.15, 0.69; p value of test of linear trend = 0.001).


View this table:
[in this window]
[in a new window]
 
TABLE 3. Odds ratios (ORs) and 95% confidence intervals (CIs) of preeclampsia according to quartile of maternal plasma antioxidant concentrations, Lima, Peru, 1997–1998

 
There was a positive relation between the plasma concentrations of {alpha}-tocopherol with the risk of preeclampsia. The risk of preeclampsia increased with successively higher quartiles of plasma {alpha}-tocopherol (OR = 1.00, 1.24, 1.26, 2.38, with the lowest quartile as referent; p value for test of linear trend = 0.0085). After controlling for confounding by maternal age, nulliparity, the prepregnancy body mass index, prenatal vitamin use, gestational age at blood collection, maternal educational attainment, whether the pregnancy was planned, and plasma cholesterol concentrations, women in the highest quartile of {alpha}-tocopherol experienced an almost fivefold increased risk of preeclampsia as compared with women in the lowest quartile (adjusted OR = 4.98; 95 percent CI: 1.77, 13.98). A similar pattern, though with slightly attenuated odds ratios, was noted when {alpha}-tocopherol was expressed as a ratio with total cholesterol or total lipids. After adjusting for the same confounders, women in the highest quartile of the ratio of plasma {alpha}-tocopherol to plasma total cholesterol experienced a 3.5-fold increased risk of preeclampsia as compared with women in the lowest quartile (adjusted OR = 3.47; 95 percent CI: 1.60, 7.57). The odds ratios for successively higher quartiles (with the lowest quartile as the referent group) were 1.00, 1.43, 1.22, and 3.13 when {alpha}-tocopherol was expressed as the ratio with total lipids. There were no clear patterns of preeclampsia risk associated with plasma concentrations of {alpha}-carotene, ß-carotene, ß-cryptoxanthin, lutein, lycopene, zeaxanthin, and {gamma}-tocopherol, respectively.


    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
This case-control study demonstrates decreased retinol and increased {alpha}-tocopherol plasma concentrations in women with preeclampsia compared with normotensive pregnant women. The relative risk of preeclampsia decreased across increasing quartiles of plasma retinol concentrations. The relative risk of preeclampsia, however, increased with successively higher quartiles of plasma {alpha}-tocopherol concentrations. The positive association between preeclampsia risk and {alpha}-tocopherol remained, though somewhat attenuated, even after the antioxidant was expressed as a ratio with plasma total cholesterol or total lipid concentrations. Plasma concentrations of {alpha}-carotene, ß-carotene, lutein, lycopene, zeaxanthin, and {gamma}-tocopherol were not associated with preeclampsia risk in this population.

Epidemiologic studies relating plasma concentrations of lipid-soluble antioxidants or prooxidants to preeclampsia risk are limited. Furthermore, inferences from the few available prior studies have been limited by their relatively small sample size and their inconsistent findings. Results from previous studies of maternal plasma carotenoids in preeclamptic and normotensive pregnant women, for instance, have been inconsistent (9Go, 28Go, 29Go). Our results are in agreement with those of Jendryczko and Drozdz (29Go), who reported that plasma concentrations of {alpha}-carotene, ß-carotene, lutein, and lycopene were similar for preeclamptic women and normotensive pregnant women. Our results, however, did not corroborate the findings reported by Ziari et al. (28Go), who noted that the mean plasma ß-carotene concentrations among preeclamptic women were 40 percent lower as compared with the mean concentrations in normotensive pregnant West African women.

Relatively few investigators have assessed the extent to which maternal retinol concentrations are altered in preeclamptic versus normotensive pregnancies. Our finding of decreased retinol concentrations in preeclamptic pregnancies is consistent with results from previous studies (28Go, 29Go). Ziari et al. (28Go) noted that mean maternal plasma retinol concentrations were 37 percent lower in the nine preeclampsia cases studied as compared with 16 normotensive controls (15.3 mg/dl vs. 24.2 mg/dl; p < 0.01).

Results from previous studies have suggested that alterations in maternal plasma or serum {alpha}-tocopherol concentrations are associated with preeclampsia. Several investigators have noted that women with preeclampsia, as compared with normotensive pregnant women, have lower {alpha}-tocopherol concentrations (9Go, 28Go, 30Go, 31Go). Other investigators (13Go, 15Go), however, have reported that preeclamptics have higher mean {alpha}-tocopherol concentrations as compared with normotensive controls. In a study of women delivering in the Tampere University Hospital, Finland, Uotila et al. (13Go) reported that women with severe preeclampsia had {alpha}-tocopherol concentrations that were 25 percent higher than concentrations measured in normotensive pregnant women (mean plasma concentrations of 39.0 (standard error (SE), 8.6) vs. 31.2 (SE, 5.9) µmol/liter; mean gestational age at sampling of 34.3 (SE, 2.2) vs. 35.3 (SE, 1.5) weeks). This finding of elevated {alpha}-tocopherol among preeclamptic women as compared with normotensive pregnant women was corroborated by Schiff et al. (15Go). In their study of US women, the authors noted that mean maternal plasma {alpha}-tocopherol concentrations were 20 percent higher in preeclampsia cases as compared with controls (1.43 (SE, 0.46) vs. 1.15 (SE, 0.32) mg/dl). In accordance with the results reported by Uotila et al. (13Go) and Schiff et al. (15Go), we noted that mean plasma {alpha}-tocopherol concentrations were 11 percent higher in cases as compared with controls. Moreover, we observed a statistically significant linear trend in the risk of preeclampsia across increasing quartiles of {alpha}-tocopherol concentrations.

Differences in study design, limited statistical power, differences in population characteristics (such as maternal age, race/ethnicity, and country of residence), failure to adjust for gestational age at blood collection, and failure to adjust lipophilic antioxidants for maternal lipid status may all have contributed to inconsistencies in results from previous studies. Variations in gestational age-specific plasma volume expansion and hyperlipidemia, for instance, have generally not been accounted for in most previous studies. We adjusted for gestational age at blood collection as a means to control for confounding by maternal plasma volume expansion. Furthermore, we controlled for potential confounding by maternal hyperlipidemia in three ways. We adjusted for plasma total cholesterol or total plasma lipids when analyzing the relation of plasma antioxidants with the risk of preeclampsia. We also calculated the ratio of plasma {alpha}-tocopherol to plasma total cholesterol and the ratio of plasma {alpha}-tocopherol to plasma total lipids as suggested by some previous investigators (21Go, 22Go, 24Go).

Potential limitations and strengths of our research must be considered when interpreting our results. First, because maternal blood samples were collected when preeclampsia became clinically evident, we cannot determine whether the observed associations between maternal plasma concentrations of antioxidants may be attributable to disease-related alterations in maternal antioxidant metabolism or whether the alterations in plasma antioxidant concentrations are causally related to preeclampsia. Second, lack of information pertaining to maternal dietary habits limited our ability to assess maternal dietary intake of these antioxidants and the risk of preeclampsia. Moreover, we were not able to measure the water-soluble antioxidant, ascorbic acid, and antioxidant enzymes including superoxide dismutase and glutathione peroxidase. Ascorbic acid and antioxidant enzymes, as well as the lipid-soluble antioxidants we studied, are all important in the defense against oxidative stress (9Go). Ascorbic acid, for instance, is known to function as the first-line antioxidant defense against free oxygen radicals present primarily in plasma (32Go). {alpha}-Tocopherol and ascorbic acid have been shown to act syngeristically (33Go, 34Go) in preventing lipid peroxidation in vitro. Specifically, results from quantitative studies designed to directly measure antioxidant consumption and free radical generation under controlled systems have confirmed the antioxidant activities of {alpha}-tocopherol in early stages of low density lipoprotein oxidation (35Go). However, under identical experimental conditions {alpha}-tocopherol, in the absence of ascorbic acid, has been shown to act as a chain-transfer agent (prooxidant). These observations suggest that our inability to measure ascorbic acid limited our capacity to fully explore the relation between maternal antioxidant status and preeclampsia.

The relatively large sample size of our study allowed us to assess relative risk estimates for preeclampsia with varying concentrations of antioxidants while adjusting for potential confounders. Nonetheless, we cannot exclude the possibility that residual confounding may still have affected the reported odds ratios. Differential misclassification of maternal plasma antioxidant concentrations is unlikely, as all laboratory analyses were conducted without knowledge of participants' pregnancy outcome.

Our results together with those from previous studies (1Go, 2Go, 9Go, 10Go, 13Go, 15Go, 28Go, 30Go, 31Go) suggest a paradoxic relation between maternal plasma antioxidants and preeclampsia risk. The pathophysiologic mechanisms for the observed association are not yet fully understood. However, several lines of evidence suggest that possible biologic mechanisms for the association between elevated {alpha}-tocopherol and increased peroxidation in preeclampsia are complex. As noted earlier, results from in vitro studies suggested that, in the absence of aqueous antioxidants, such as ascorbic acid, {alpha}-tocopherol can act as a prooxidant (36GoGoGoGo–40Go). It is possible that, under the physiologic oxidative stress commonly identified in preeclampsia, after first-line defense antioxidants such as ascorbate acid are consumed, high concentrations of {alpha}-tocopherol may act as a prooxidant rather than as an antioxidant. The increased plasma concentrations of {alpha}-tocopherol in preeclamptic women may also be a compensatory increase in response to the elevated oxidative stress of preeclampsia, as suggested by a previous study (13Go).

Moreover, elevated {alpha}-tocopherol in preeclamptic, compared with normotensive, women may, in part, be attributed to altered placental physiology. Extensive changes in the placenta including thickening of the trophoblastic basement membrane, placental infarction, proliferation of the cytotrophoblast, and retroplacental hematoma have been observed in preeclamptic women more frequently than in normotensive pregnant women (41Go). It is likely that preeclampsia-related placental abnormalities may result in a decrease in the transfer of some nutrients, including {alpha}-tocopherol, to the fetus. As a result, more {alpha}-tocopherol will be retained in the maternal circulation in preeclamptic women compared with normotensive pregnant women. Additional studies of the placental transfer of antioxidant vitamins in preeclamptic and normotensive pregnancy are needed.

In summary, we have shown that plasma retinol concentrations were negatively associated with an increased risk of preeclampsia. Plasma {alpha}-tocopherol concentrations, however, were positively associated with an increased risk of preeclampsia. This association persisted after controlling for maternal plasma lipid status and other potential confounding factors. Although the biologic mechanisms for this statistical association are presently not well understood, our results, when taken together with those of others, suggest that preeclampsia may not be a state of global antioxidant deficiency in maternal peripheral circulation. Future prospective longitudinal studies involving measurements of concentrations of antioxidant nutrients and enzymes in blood and placental tissue are needed to confirm and expand upon our findings. Information about maternal dietary intake and use of dietary supplements of antioxidants should also be collected in future studies. At present, the results from our study and those of others (1Go, 2Go, 9Go, 10Go, 13Go, 15Go, 28Go, 30Go, 31Go) suggest that the role of {alpha}-tocopherol in the pathogenesis of preeclampsia may be complex.


    ACKNOWLEDGMENTS
 
This research was supported by awards from the National Institutes of Health (T37-TW00049 and HD/HL R01-32562).

The authors thank Mirtha Grande, Elena Sanchez, Nelly Toledo, Hong Tang, Mohammed Adem, and June Hu for their skillful technical assistance.


    NOTES
 
Reprint requests to Dr. Cuilin Zhang, Department of Epidemiology, Box 357236, University of Washington, 1959 Northeast Pacific, Seattle, WA 98195 (e-mail: clinn{at}u.washington.edu).


    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Sagol S, Ozkinay E, Ozsener S. Impaired antioxidant activity in women with pre-eclampsia. Int J Gynaecol Obstet 1999;64:121–7.[ISI][Medline]
  2. Hubel CA, Roberts JM, Taylor RN, et al. Lipid peroxidation in pregnancy: new perspectives on preeclampsia. Am J Obstet Gynecol 1989;161:1025–34.[ISI][Medline]
  3. Roberts JM, Taylor RN, Goldfen A. Clinical and biochemical evidence of endothelial cell dysfunction in the pregnancy syndrome preeclampsia. Am J Hypertens 1991;4:700–8.[ISI][Medline]
  4. Roberts JM, Taylor RN, Musci TJ, et al. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 1989;161:1200–4.[ISI][Medline]
  5. Lockwood CJ, Peters JH. Increased plasma levels of ED1+ cellular fibronectin precede the clinical signs of preeclampsia. Am J Obstet Gynecol 1990;162:358–62.[ISI][Medline]
  6. Taylor RN, Crombleholme WR, Friedman SA, et al. High plasma cellular fibronectin levels correlate with biochemical and clinical features of preeclampsia but cannot be attributed to hypertension alone. Am J Obstet Gynecol 1991;165:895–901.[ISI][Medline]
  7. Roberts JM. Endothelial dysfunction in preeclampsia. Semin Reprod Endocrinol 1998;16:5–15.[ISI][Medline]
  8. Davidge ST. Oxidative stress and altered endothelial cell function in preeclampsia. Semin Reprod Endocrinol 1998;16:65–73.[ISI][Medline]
  9. Mikhail MS, Anyaegbunam A, Garfinkel D, et al. Preeclampsia and antioxidant nutrients: decreased plasma levels of reduced ascorbic acid, alpha-tocopherol, and beta-carotene in women with preeclampsia. Am J Obstet Gynecol 1994;171:150–7.[ISI][Medline]
  10. Davidge ST, Hubel CA, Brayden RD, et al. Sera antioxidant activity in uncomplicated and preeclamptic pregnancies. Obstet Gynecol 1992;79:897–901.[Abstract]
  11. Wisdom SJ, Wilson R, McKillop JH, et al. Antioxidant systems in normal pregnancy and in pregnancy-induced hypertension. Am J Obstet Gynecol 1992;167:1701–4.
  12. Wang Y, Walsh SW, Kay HH. Placental lipid peroxides and thromboxane are increased and prostacyclin is decreased in women with preeclampsia. Am J Obstet Gynecol 1992;167:946–9.[ISI][Medline]
  13. Uotila JT, Tuimala RJ, Aarnio TM, et al. Findings on lipid peroxidation and antioxidant function in hypertensive complications of pregnancy. Br J Obstet Gynaecol 1993;100:270–6.[ISI][Medline]
  14. Morris JM, Gopaul NK, Endresen MJ, et al. Circulating markers of oxidative stress are raised in normal pregnancy and pre-eclampsia. Br J Obstet Gynaecol 1998;105:1195–9.[ISI][Medline]
  15. Schiff E, Friedman SA, Stampfer M, et al. Dietary consumption and plasma concentrations of vitamin E in pregnancies complicated by preeclampsia. Am J Obstet Gynecol 1996;175:1024–8.[ISI][Medline]
  16. Sanchez SE, Zhang C, Williams MA, et al. Tumor necrosis factor-{alpha} soluble receptor p55 (sTNFp55) and risk of preeclampsia in Peruvian women. J Reprod Immunol 2000;47:49–63.[ISI][Medline]
  17. Sanchez SE, Zhang C, Malinow MR, et al. Plasma folate, vitamin B12, and homocyst(e)ine concentrations in preeclamptic and normotensive Peruvian women. Am J Epidemiol (in press).
  18. Ware-Jauregui S, Sanchez SE, Zhang C, et al. Plasma lipid concentrations in pre-eclamptic and normotensive Peruvian women. Int J Gynaecol Obstet 1999;67:147–55.[ISI][Medline]
  19. Bruinse HW, van den Berg H. Changes of some vitamin levels during and after normal pregnancy. Eur J Obstet Gynecol Reprod Biol 1995;61:31–7.[ISI][Medline]
  20. Kalman DA, Goodman GE, Omenn GS, et al. Micronutrient assay for cancer prevention clinical trials: serum retinol, retinyl palmitate, alpha-carotene, and beta-carotene with the use of high-performance liquid chromatography. J Natl Cancer Inst 1987;79:975–82.[ISI][Medline]
  21. Margetts BM, Nelson M. Design concepts in nutritional epidemiology. 2nd ed. New York, NY: Oxford University Press, Inc, 1997.
  22. Thurnham DI, Davies JA, Crump BJ, et al. The use of different lipids to express serum tocopherol: lipid ratios for the measurement of vitamin E status. Ann Clin Biochem 1986;23:514–20.[ISI][Medline]
  23. Thurnham DI. Antioxidants and pro-oxidants in malnourished populations. Proc Nutr Soc 1990;49:247–59.[ISI][Medline]
  24. Willett W. Nutritional epidemiology. 2nd ed. New York, NY: Oxford University Press, Inc, 1998.
  25. Haga P, Ek J, Kran S. Plasma tocopherol levels and vitamin E/B lipoprotein relationships during pregnancy and in cord blood. Am J Clin Nutr 1982;36:1200–4.[Abstract]
  26. Mantel N. Chi-square tests with one degree of freedom: extensions of Mantel-Haenszel procedure. J Am Stat Assoc 1963;58:690–700.[ISI]
  27. Rothman KJ, Greenland S. Modern epidemiology. 2nd ed. Philadelphia, PA: Lippincott-Raven Publishers, 1998.
  28. Ziari SA, Mireles VL, Cantu CG, et al. Serum vitamin A, vitamin E, and beta-carotene levels in preeclamptic women in northern Nigeria. Am J Perinatol 1996;13:287–91.[ISI][Medline]
  29. Jendryczko A, Droz;dz M. Plasma retinol, ß-carotene, and vi-tamin E levels in relation to the future risk of preeclampsia. Zentralbl Gynakol 1989;111:1121–3.[ISI][Medline]
  30. Sushil KJ, Rodney W. Relationship between elevated lipid peroxides, vitamin E deficiency, and hypertension in preeclampsia. Mol Cell Biochem 1995;151:33–8.[ISI][Medline]
  31. Yanik FF, Amanvermez R, Yanik A, et al. Preeclampsia and eclampsia associated with increased lipid peroxidation and decreased serum vitamin E levels. Int J Gynaecol Obstet 1999;64:27–33.[ISI][Medline]
  32. Wefers M, Sies H. The protection by ascorbate and glutathione against microsomal lipid peroxidation is dependent on vitamin E. Exp J Biochem 1988;174:353–7.
  33. Packer JE, Slater TF, Willson RL. Direct observation of a free radical interaction between vitamin E and vitamin C. Nature 1979;278:737–8.[ISI][Medline]
  34. Chan AC. Partners in defense, vitamin E and vitamin C. Can J Physiol Pharmacol 1993;71:725–31.[ISI][Medline]
  35. Ingold KU, Bowry VW, Stocker R, et al. Autoxidation of lipids and antioxidation by {alpha}-tocopherol and ubiquinol in homogeneous solution and in aqueous dispersions of lipids: unrecognized consequences of lipid particle size as exemplified by oxidation of human low density lipoprotein. Proc Natl Acad Sci U S A 1993;90:45–9.[Abstract]
  36. Nagaoka S, Okauchi Y, Urano S, et al. Kinetic and ab initio study of the prooxidant effect of vitamin E. Hydrogen abstraction from fatty acid esters and egg yolk lecithin. J Am Chem Soc 1990;112:8921–4.[ISI]
  37. Mukai K. Synthesis and kinetic study of antioxidant and prooxidant actions of vitamin E derivatives. In: Packer L, Fuchs J, eds. Vitamin E in health and disease. New York, NY: Mercel Dekker, Inc, 1993:9–119.
  38. Bowry VW, Ingold KU, Stocker R. Vitamin E in human low-density lipoprotein--when and how this antioxidant becomes a pro-oxidant. Biochem J 1992;288:341–4.[ISI][Medline]
  39. Stocker R, Bowry VW, Frei B. Ubiquinol-10 protects human low density lipoprotein more efficiently against lipid peroxidation than {alpha}-tocopherol. Proc Natl Acad Sci U S A 1991;88:1646–50.[Abstract]
  40. Kontush A, Finckh B, Karten B, et al. Antioxidant and prooxidant activity of {alpha}-tocopherol in human plasma and low density lipoprotein. J Lipid Res 1996;37:1436–48.[Abstract]
  41. Fox H. The placenta in maternal disorders. In: Pathology of the placentae. London, England: WB Saunders, 1978:214–22.
Received for publication March 20, 2000. Accepted for publication July 18, 2000.